renal impairment

Updated: July 27, 2022

Background

Epidemiology

Anatomy

Pathophysiology

Etiology

Genetics

Prognostic Factors

Clinical History

Physical Examination

Age group

Associated comorbidity

Associated activity

Acuity of presentation

Differential Diagnoses

Laboratory Studies

Imaging Studies

Procedures

Histologic Findings

Staging

Treatment Paradigm

by Stage

by Modality

Chemotherapy

Radiation Therapy

Surgical Interventions

Hormone Therapy

Immunotherapy

Hyperthermia

Photodynamic Therapy

Stem Cell Transplant

Targeted Therapy

Palliative Care

Medication

azlocillin

For creatinine clearance <30ml/min:

Intravenous (IV)

every 8 hrs

increased at 12hr intervals
Dose reduction may be required in case of hepatic impairment

carboplatin

CrCl 41-59 mL/min: 250 mg/m² Intravenous on day 1
CrCl 16-40 mL/min: 200 mg/m² Intravenous on day 1
CrCl <15 mL/min: usually not recommended

margetuximab

Mild-to-moderate (CrCl 30-89 mL/min): No dose adjustment is needed
Severe (CrCl 15-29 mL/min), end-stage renal disease with or without hemodialysis) Unknown

aminosalicylic acid

CrCl below 10 mL/min: reduce dosage by 50%
CrCl 10 to 50 mL/min: reduce dosage by 25-50%
Haemodialysis: give 50% of dose following dialysis
Hepatic impairment: use caution

betaxolol

5 mg orally every Day may be gradually increased every two weeks, The maximum dosage is 20 mg

dextroamphetamine transdermal

If the patient's (GFR) ranges from 15 to <30 mL/min/1.73 m², the dose of the medication should not exceed 13.5 mg/9 hour
If the patient has end-stage renal disease and their GFR is <15 mL/min/1.73 m²,maximum dosage of the medication is 9 mg every 9 hours
It is important to note that dextroamphetamine cannot be removed by dialysis

azlocillin

Infants 7 days to 1yr:

mg/kg

Intravenous (IV)

3 times a day

For neonates <7 days: 50mg/kg twice a day
For creatinine clearance <30ml/min (children up to 14yr): 2g IV every 8 hours increased at 12hr intervals
Dose reduction may be required in case of hepatic impairment

dextroamphetamine transdermal

Having (GFR 15 to less than 30 mL/min/1.73 m2) should not receive a dose of more than 13.5 mg/9 hours
Patients with end-stage renal disease (GFR less than 15 mL/min/1.73 m2) should not receive a dose of more than 9 mg/9 hours
It is important to note that dextroamphetamine cannot be removed by dialysis

Future Trends